Product Information
CARBAMAZEPINE 200 MG TABLET is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.1194 per EA under NDC 75834022101. Its NADAC has been published 317 times since Sep 9, 2020.
FDA first approved this application on Apr 15, 2020. Its Orange Book therapeutic-equivalence code is BX.
Strength
200 mg/1
Manufacturer
Nivagen Pharmaceuticals Inc.NDC
75834022101
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBAMAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA207798FDA Approved
4/15/2020
TE Code
BX
On Market Since
4/21/2020
Pharmacological Classes
Price Statistics
The NADAC for CARBAMAZEPINE 200 MG TABLET has been published 317 times since Sep 9, 2020, and over the history we have for it it has declined 61.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1194 per EA |
|---|---|
| All-time high | $0.3113 (Sep 16, 2020) |
| All-time low | $0.1005 (Jul 17, 2024) |
| 52-week high | $0.1261 |
| 52-week low | $0.1157 |
| Median price | $0.1566 |
| Average price | $0.1757 |
| Largest weekly change | +96.7% (Aug 28, 2024) |
| Weeks tracked | 317 |
| Tracking since | Sep 9, 2020 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Nivagen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbamazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBAMAZEPINE 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CARBAMAZEPINE 200 MG TABLET, manufactured by Nivagen Pharmaceuticals Inc., is $0.1194 per EA (NDC 75834022101), effective Sep 30, 2026.
How has the price of CARBAMAZEPINE 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for CARBAMAZEPINE 200 MG TABLET has declined 61.6%. It has been tracked across 317 weekly CMS publications since Sep 9, 2020.
What are the highest and lowest recorded NADAC prices for CARBAMAZEPINE 200 MG TABLET?
Since Sep 9, 2020, the NADAC for CARBAMAZEPINE 200 MG TABLET has ranged from a low of $0.1005 (Jul 17, 2024) to a high of $0.3113 (Sep 16, 2020), with a median of $0.1566 per EA.
Are there cheaper alternatives to CARBAMAZEPINE 200 MG TABLET?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBAMAZEPINE 200 MG TABLET, is $0.1170 per EA — about 2% below CARBAMAZEPINE 200 MG TABLET.
Who manufactures CARBAMAZEPINE 200 MG TABLET?
CARBAMAZEPINE 200 MG TABLET (NDC 75834022101) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.